|
1
|
Li F, Zhao C and Wang L:
Molecular-targeted agents combination therapy for cancer:
Developments and potentials. Intl J Cancer. 134:1257–1269. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Olofsson B: Rho guanine dissociation
inhibitors: Pivotal molecules in cellular signalling. Cell Signal.
11:545–554. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sasaki T and Takai Y: The Rho small G
protein family-Rho GDI system as a temporal and spatial determinant
for cytoskeletal control. Biochem Biophys Res Commun. 245:641–645.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Golovanov AP, Chuang TH, DerMardirossian
C, Barsukov I, Hawkins D, Badii R, Bokoch GM, Lian LY and Roberts
GC: Structure-activity relationships in flexible protein domains:
Regulation of rho GTPases by RhoGDI and D4 GDI. J Mol Biol.
305:121–135. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang B, Zhang Y, Dagher MC and Shacter E:
Rho GDP dissociation inhibitor protects cancer cells against
drug-induced apoptosis. Cancer Res. 65:6054–6062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Poland J, Schadendorf D, Lage H, Schnolzer
M, Celis JE and Sinha P: Study of therapy resistance in cancer
cells with functional proteome analysis. Clin Chem Lab Med.
40:221–234. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sinha P, Kohl S, Fischer J, Hütter G, Kern
M, Köttgen E, Dietel M, Lage H, Schnölzer M and Schadendorf D:
Identification of novel proteins associated with the development of
chemoresistance in malignant melanoma using two-dimensional
electrophoresis. Electrophoresis. 21:3048–3057. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao L, Wang H, Li J, Liu Y and Ding Y:
Overexpression of Rho GDP-dissociation inhibitor alpha is
associated with tumor progression and poor prognosis of colorectal
cancer. J Proteome Res. 7:3994–4003. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peng X, Xie G, Wang Z, Lin H, Zhou T,
Xiang P, Jiang Y, Yang S, Wei Y, Yu L, et al: SKLB-163, a new
benzothiazole-2-thiol derivative, exhibits potent anticancer
activity by affecting RhoGDI/JNK-1 signaling pathway. Cell Death
Dis. 5:e11432014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Z, Shi XH, Wang J, Zhou T, Xu YZ,
Huang TT, Li YF, Zhao YL, Yang L, Yang SY, et al: Synthesis,
structure-activity relationships and preliminary antitumor
evaluation of benzothiazole-2-thiol derivatives as novel apoptosis
inducers. Bioorg Med Chem Lett. 21:1097–1101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi W, Tang Q, Chen X, Cheng P, Jiang P,
Jing X, Chen X, Chen P, Wang Y, Wei Y, et al: Antitumor and
antimetastatic activities of vesicular stomatitis virus matrix
protein in a murine model of breast cancer. J Mol Med Berl.
87:493–506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hutchinson I, Chua MS, Browne HL, Trapani
V, Bradshaw TD, Westwell AD and Stevens MF: Antitumor
benzothiazoles. 14. Synthesis and in vitro biological properties of
fluorinated 2-(4-aminophenyl) benzothiazoles. J Med Chem.
44:1446–1455. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kok SH, Gambari R, Chui CH, Yuen MC, Lin
E, Wong RS, Lau FY, Cheng GY, Lam WS and Chan SH: Synthesis and
anti-cancer activity of benzothiazole containing phthalimide on
human carcinoma cell lines. Bioorg Med Chem. 16:3626–3631. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Trapani G, Franco M, Latrofa A, Reho A and
Liso G: Synthesis, in vitro and in vivo cytotoxicity, and
prediction of the intestinal absorption of substituted
2-ethoxycarbonyl-imidazo[2,1-b] benzothiazoles. Eur J Pharm Sci.
14:209–216. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song EY, Kaur N, Park MY, Jin Y, Lee K,
Kim G, Lee KY, Yang JS, Shin JH, Nam KY, et al: Synthesis of amide
and urea derivatives of benzothiazole as Raf-1 inhibitor. Eur J Med
Chem. 43:1519–1524. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Srimanth K, Rao VR and Krishna DR:
Synthesis and evaluation of anticancer activity of some
imidazothiazolyl, imidazobenzothiazolyl and dihydroimidazothiazolyl
coumarins. Arzneimittelforschung. 52:388–392. 2002.PubMed/NCBI
|
